BioProject

Cytarabine is one of the first line chemo drugs to treat acute myeloid leukemia (AML). More...

Cytarabine is one of the first line chemo drugs to treat acute myeloid leukemia (AML). However, cytarabine can induce AML cell cell cycle arrest at G0/G1 phase. These cell-cycle-arrested AML cells resist cytarabine, show a senescence-like phenotype or stem-cell like phenotype. To eliminate these cell-cycle arrested cells, we developed a FL-Fc-DM1 drug by conjugating FLT3 liangd Fc fusion protein and mertansine. We used the THP-1 cells as a AML model. The total mRNA of THP-1 cells treated with different drugs (cytarabine, FL-Fc-DM1, FL-Fc) were sequenced. Overall design: THP-1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS. In the control group, THP-1 cells were cultured for 4 days. In the cytarabine group, THP-1 cells were treated with 20 µM cytarabine for 4 days. In the FL-Fc-DM1 treatment group, THP-1 cells were treated by cytarabine for 3 days and then treated with FL-Fc-DM1 (5 nM) for another 24 hours in the absence of cytarabine. In the FL-Fc treatment group, THP-1 cells were treated by cytarabine for 3 days and then treated with FL-Fc (5 nM) for another 24 hours in the absence of cytarabine. We than analyze the transcriptome differences between different groups. Less...